• Astrocytic GAT-3 Modulation of Dentate Gyrus Synaptic Transm

  2026-07-31

  This study reveals that astrocytic GAT-3 regulates synaptic transmission and memory formation in the hippocampal dentate gyrus by linking GABA transporter activity to astrocytic Ca2+ signaling and presynaptic glutamatergic modulation. These findings clarify a pivotal glial mechanism underlying contextual memory and highlight new research avenues for cognitive disorders.

• MiR-3180 Suppresses HCC via Lipid Metabolic Pathway Targetin

  2026-07-31

  Hong et al. identified miR-3180 as a critical suppressor of hepatocellular carcinoma (HCC) progression through coordinated inhibition of both de novo fatty acid synthesis and lipid uptake. This work highlights miR-3180 as a promising prognostic marker and therapeutic target, advancing our understanding of metabolic regulation in cancer.

• MG-132 (Z-LLL-al): Redefining Proteasome Inhibition in Cance

  2026-07-30

  Explore the advanced scientific applications of MG-132 in modulating the ubiquitin-proteasome system and metabolic vulnerabilities in cancer cells. This article delivers a unique, mechanism-driven perspective on MG-132 (Z-LLL-al), integrating novel insights from recent NAD+ metabolic research.

• IGFBP2-THBS1 Axis Mediates GH-Induced Bone Growth in ISS

  2026-07-30

  This study reveals that recombinant human growth hormone (GH) promotes bone growth in idiopathic short stature (ISS) by activating the IGF-1 pathway through IGFBP2-mediated inhibition of THBS1. The findings elucidate a novel molecular axis underlying GH therapy efficacy and suggest IGFBP2 and THBS1 as potential targets for optimizing ISS treatment.

• Superoxide Dismutase (SOD) Activity Assay Kit: Technical Gui

  2026-07-29

  The Superoxide Dismutase (SOD) Activity Assay Kit enables rapid, quantitative assessment of SOD enzyme activity in biological fluids, supporting research into oxidative stress and antioxidative mechanisms. It is not suitable for clinical diagnostics or medical decision-making, but is optimized for research workflows requiring sensitive, colorimetric detection of SOD activity.

• 2'3'-cGAMP (sodium salt): Tumor Immune Evasion and ENPP1 Ins

  2026-07-29

  Explore how 2'3'-cGAMP (sodium salt) illuminates tumor immune evasion via ENPP1-mediated hydrolysis and advances STING pathway research. This article uniquely integrates mechanistic, translational, and protocol-level insights for immunology and cancer research.

• Astrocytic GAT-3 Controls Synaptic Transmission and Memory i

  2026-07-28

  This study uncovers a pivotal mechanism by which astrocytic GAT-3 regulates synaptic transmission and memory formation in the dentate gyrus. Through multimodal experiments, the authors reveal that GAT-3-mediated astrocytic calcium signaling modulates both neurotransmitter release and cognitive processing, providing new targets for synaptic and memory research.

• Patient-Derived Gastric Cancer Assembloids Advance Drug Mode

  2026-07-28

  Shapira-Netanelov et al. (2025) describe a novel patient-derived gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal subpopulations, capturing the complexity of the tumor microenvironment. This approach yields more physiologically relevant platforms for studying tumor–stroma interactions, resistance mechanisms, and drug response variability, marking a significant advance for translational oncology research.

• Berberrubine Mitigates NAFLD by Targeting Metabolic and Micr

  2026-07-27

  This study demonstrates that berberrubine, a primary metabolite of berberine, alleviates non-alcoholic fatty liver disease in vivo by modulating glucose and lipid metabolism and restoring gut microbiota balance. The research provides novel mechanistic insights and suggests berberrubine as a promising therapeutic candidate for NAFLD.

• EDI3 Inhibition Reduces Viability in HER2+ Breast Cancer Mod

  2026-07-27

  Keller et al. uncover the role of glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer, especially in the context of resistance to HER2-targeted therapies. Their study demonstrates that targeting EDI3 decreases cell viability and tumor growth, identifying EDI3 as a promising therapeutic target for overcoming HER2 therapy resistance.

• Streptavidin-HyperFluor 647: Precision Tools for Translation

  2026-07-26

  This article dissects how Streptavidin-HyperFluor 647 elevates the fidelity and sensitivity of biotinylated molecule detection in advanced proteomic workflows. By integrating mechanistic insight, recent innovations in proximity labeling, and strategic recommendations for translational researchers, we deliver a forward-thinking perspective on optimizing red-fluorescent streptavidin conjugates for microscopy, flow cytometry, and FRET. Key findings from contemporary biotin-free labeling studies are synthesized with practical guidance to help scientists navigate the evolving landscape of subcellular proteome profiling, especially in challenging primary cell systems.

• CGP 55845 Hydrochloride: Precision GABAB Receptor Antagonist

  2026-07-25

  CGP 55845 hydrochloride offers unmatched selectivity and potency for dissecting GABAB receptor-mediated neurotransmission. Its application in in vitro workflows empowers researchers to unravel astrocyte-neuron interactions, optimize synaptic modulation assays, and troubleshoot GABAergic circuit studies with confidence.

• 4-Methylumbelliferyl-β-D-Glucopyranoside: Enabling Precision

  2026-07-24

  Explore how 4-Methylumbelliferyl-β-D-Glucopyranoside (4-MUG) empowers next-generation β-glucosidase and β-glucocerebrosidase activity assays. This article delivers a unique, in-depth look at assay optimization, glycosphingolipid metabolism research, and the translational bridge from basic discovery to mRNA-based therapy development.

• 4-Methylumbelliferyl-β-D-Glucopyranoside in Lysosomal Enzyme

  2026-07-24

  4-Methylumbelliferyl-β-D-Glucopyranoside (4-MUG) enables high-sensitivity, quantitative assessment of β-glucosidase and β-glucocerebrosidase activity, now pivotal in mRNA-based Gaucher disease research. Learn how optimized workflows, protocol parameters, and troubleshooting strategies with 4-MUG empower translational enzyme activity studies and high-throughput inhibitor screening.

• Masitinib (AB1010): Technical Guide for KIT/PDGFR Research

  2026-07-23

  Masitinib (AB1010) is a selective phenylaminothiazole-type tyrosine kinase inhibitor designed for precise targeting of KIT, PDGFRα, and PDGFRβ. It is optimized for use in DMSO-based cancer biology, mastocytosis, and inflammatory disease research workflows, but is not suitable for protocols requiring aqueous or ethanol solubility, or broad-spectrum kinase inhibition.

11696 records 1/780 page Next 12345 下5页 Last page